We are an independent, global, inter-disciplinary, non-partisan group of policy-makers, scholars, scientists, strategists and others convened to think through the wide range of issues and crises associated with the Covid-19 pandemic. The Commission’s purpose is to enable informed discourse and decision-making, to frame priorities and help build consensus on policy solutions to strengthen societal and global resilience. The full list of Commissioners can be found here.


By Bill Emmott and Berel Rodal, co-directors, GCPPP, November 28th 2021

The Global Commission’s assessment of the state of the world amid what needs to be treated by policy-makers as “the perpetual pandemic”, and considered as part of four mutually reinforcing crises, of health/biology, ecology/climate, trust/legitimacy and geopolitics/international order.

Leading Indicators

Since production began in November 2020 of COVID-19 vaccines, data assembled by our partners Airfinity show that the world’s manufacturers had by the end of 2021 made more than 10.9 billion doses. This is a lot more than was expected in the early months of 2021 when manufacturing hiccups and supply shortages made the struggle look very steeply uphill. In the month of December a big jump in output in Pfizer’s European Union factories and a sharp revival in output by the two Chinese giants, Sinopharm and Sinovac, enabled more than 1.5 billion doses to be made, a 50% rise on November’s figure. In 2021 as a whole the top four producers each made well over 2 billion doses, putting them far ahead of Moderna and other contenders.

What South Africa tells us about Omicron

By Dylan Barry, GCPPP staff, Johannesburg, January 21st 2022

In this ANALYSIS—reported from the ground in South Africa—we summarise Omicron’s trajectory in the country, how the government’s response to Omicron differed from its response to previous coronavirus strains, and what lessons can be drawn from South Africa’s discovery of and response to Omicron. Next week, we will publish an article surveying what is known and not known about Omicron more broadly: its origins, severity, transmissibility, interaction with vaccines and variability.

On early-warning systems

By Lara von der Brelie, GCPPP Staff, December 14th 2021

If only we had known sooner – or could know in time on the next occasion. Putting in place early-warning systems for future dangerous pathogens promises to be a key mission for public policy and above all for preparedness at an international level. But how? Political and practical obstacles make such a mission far from straightforward. This ANALYSIS builds on a previous Policy Monitor on the risk of Zoonotic disease transfers – viruses jumping from animals to humans – to look at the steps that could be taken, both in an ideal world and in our own far-from-ideal one.